L-Serine for ALS

(ALS Trial)

CL
SE
Overseen ByStephanie E Langlois
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines the tolerance of the supplement L-Serine in people with ALS, a nervous system disease that weakens muscles, and its potential to alleviate symptoms. Participants will take L-Serine twice daily for six months. The trial seeks individuals diagnosed with ALS within the past three years who are stable on their current ALS medications. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

Do I need to stop my current medications to join the trial?

The trial does not require you to stop your current medications, but if you are taking Riluzole or Edaravone/Radicava, you must be on a stable dose for 3 months before starting the trial. If you recently stopped these medications due to side effects, you need to wait 7 days before joining.

Is there any evidence suggesting that L-Serine is likely to be safe for humans?

Research has shown that L-Serine is generally safe for use. It is not considered a dangerous substance and does not pose major health risks when handled normally. Safety guidelines indicate no special precautions are needed, and it is not deemed harmful. However, L-Serine is flammable, so it should be kept away from open flames and food.

In past studies, participants used L-Serine without major side effects. Some minor reactions, such as skin irritation or needing fresh air if inhaled, might occur, but these are common precautions and not specific to L-Serine being particularly risky.

Overall, based on current safety information, L-Serine appears to be a safe treatment option.12345

Why do researchers think this study treatment might be promising for ALS?

Unlike the standard ALS treatments, which often focus on managing symptoms through medications like riluzole and edaravone, L-Serine offers a different approach by potentially providing neuroprotective benefits. L-Serine is a naturally occurring amino acid that may help reduce the misfolding of proteins, a process thought to contribute to ALS progression. Researchers are excited because it represents a novel way to target the disease's underlying mechanisms, which could slow its progression and improve patients' quality of life.

What evidence suggests that L-Serine might be an effective treatment for ALS?

Research has shown that L-Serine might assist with nerve and brain issues. In studies with mice, L-Serine repaired damaged white matter in the brain. Another study found that L-Serine slowed the progression of a genetic nerve disorder called HSAN1 in patients. These findings suggest that L-Serine could potentially aid in nerve and brain conditions. However, these results are not specific to ALS, the focus of this trial. More research is needed to determine its effectiveness for ALS patients. Participants in this trial will receive L-Serine to evaluate its effects on ALS.678910

Who Is on the Research Team?

EW

Elijah W Stommel, MD,PHD

Principal Investigator

Dartmouth-Htichcock Medical Center

Are You a Good Fit for This Trial?

Inclusion Criteria

Diagnosis of probable or definite ALS
ALSFRS-R score >25 and FVC score ≥ 60% predicted
If currently taking Riluzole and/or Edaravone/Radicava must be on stable dose for 3 months prior to Baseline/Screening. If the dosing has not been stable for 3 months prior to Baseline/Screening or if stopped due to an adverse event, the waiting period off the medication will be 7 days. If not on either of these medications may start if desired either or both medications after enrollment into study.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive L-Serine 15 grams orally twice a day for 6 months

6 months
Regular visits for blood draws, vital sign checks, neurological and physical exams, pulmonary testing, and questionnaires

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months
Follow-up visits after treatment period

What Are the Treatments Tested in This Trial?

Interventions

  • L-Serine
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: L-SerineExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Elijah W. Stommel

Lead Sponsor

Trials
1
Recruited
40+

Brain Chemistry Labs

Collaborator

Trials
2
Recruited
70+

Brain Chemistry Labs, Institute for Ethnomedicine

Collaborator

Trials
2
Recruited
70+

Citations

L-serine: Neurological Implications and Therapeutic PotentialL-serine supplementation of 400 mg/kg/day for 52 weeks was able to reduce the neurotoxic level of 1-deoxysphingolipds which is responsible for ...
L-Serine, an Endogenous Amino Acid, Is a Potential ...Our previous study showed that L-serine had an outstanding therapeutic effect on lysophosphatidylcholine induced white matter injury in mice, ...
Tolerability and Efficacy of L-Serine in Patients With GRIN ...AIM The purpose of this study is to determine L-Serine dietary supplement efficacy for the treatment of patients with GRIN-related disorders caused by the ...
Randomized trial of l-serine in patients with hereditary ...This study provides Class I evidence that high-dose oral l-serine supplementation significantly slows disease progression in patients with HSAN1.
Intake of l-serine before bedtime prevents the delay of the ...Our findings suggest that intake of l-serine before bedtime for multiple days might attenuate the circadian phase delay in the real world.
SAFETY DATA SHEETHandle in accordance with good industrial hygiene and safety practice. Page 4. L-Serine. Revision Date 24-Dec-2021.
SAFETY DATA SHEETL-Serine is not a hazardous substance. For skin contact, rinse with water. If inhaled, fresh air is needed. Respiratory protection is required ...
Safety Data Sheet: L-SerineL-Serine is not classified as hazardous, but is combustible. Keep away from food, drink, and animal feedingstuffs. No special handling measures are needed.
SAFETY DATA SHEETL-Serine. -3.07. No data available. Mobility in soil. The product is water soluble, and may spread in water systems Will likely be mobile in the.
SAFETY DATA SHEETHazardous Combustion Products. Thermal decomposition can lead to release of irritating gases and vapors.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security